頁籤選單縮合
題名 | Screening for Ocular Toxicity in Asymptomatic Patients Treated with Tamoxifen=服用Tamoxifen患者眼部毒性之篩檢 |
---|---|
作者 | 李居仁; 楊博勝; 呂志純; 楊圳隆; 劉建良; 吳愛卿; Lee, Jie-jen; Yang, Po-sheng; Lu, Chih-chun; Yang, Tsen-long; Liu, Chien-liang; Wu, Ai-ching; |
期刊 | 中華民國外科醫學會雜誌 |
出版日期 | 19970300、19970400 |
卷期 | 30:2 民86.03-04 |
頁次 | 頁98-102 |
分類號 | 418.8 |
語文 | eng |
關鍵詞 | 眼部毒性; Tamoxifen; Ocular toxicity; Breast cancer`; |
中文摘要 | Tamoxifen是一種Estrogen的競爭性對抗劑,已被廣泛應用於乳癌患者的治療,高 劑量的 Tamoxifen 會造成一些嚴重的副作用, 由許多報告證實在眼部方面也會造成毒性, 例如在角膜的表面會形成螺旋狀的白斑、在視網膜內層會有反光性結晶物質沉積、會造成視 網膜色素上皮的異常、視神經炎及黃斑部水腫。 本研究試圖瞭解服用 Tamoxifen 但無眼部 症狀的患者,是否已有眼部毒性的發生。 在此研究中, 收集 1993 年 7 月至 1993 年 12 月間返診的乳癌術後患者,曾接受或仍在 接受 Tamoxifen 治療的患者共 75 例,全部為女性乳癌患者。其服用 Tamoxifen 的劑量為 每日 20 毫克,平均治療期間為 16.2 個月,平均的累積劑量為 9.7 ± 6.6 克,經檢查後 ,在眼部方面都未出現毒性反應。雖然如此,臨床醫師仍需牢記文獻上曾報告非常低劑量的 Tamoxifen 就會引起眼部毒性,一旦有眼部症狀,需即時停藥,以減低後續無可回復之傷害 。 |
英文摘要 | Tamoxifen is the drug of choice in the initial hormonal treatment for both premenopausal and postmenopausal women with ER-positive breast carcinoma. Generally, the drug is well tolerated, although case reports have documented ocular toxicity in patients receiving very-high-dose tamoxifen (>180 mg/d). The ocular side effects include corneal changes, optic neuritis, retinopathy, and macular edema. As the currently recommended dose of the drug is 20 mg per day, we attempted to determined the prevalence of ocular toxicity in patients treated with such a low daily dose of tamoxifen. This study included 75 breast cancer patients who had been treated with tamoxifen for variable periods of duration after surgical intervention and who had undergone ocular examinations before any visual symptoms had appeared. The mean duration of tamoxifen treatment was 16.2 months (range 2-49 months). The mean cumulative dose of the 75 patients was 9.7 ± 6.6 gm (range 1.2-31.8 gm). No tamoxifen-related ocular toxicity was noted in our study. Although our data showed no tamoxifen ocular toxicity in asymptomatic patients during the course of current tamoxifen therapy, the ocular safety of higher cumulative dosages recommended by conventional therapy is still unknown. Thus, all physicians should still be aware of the potential of ocular toxicity associated with tamoxifen and encourage baseline ophthalmologic evaluations and close monitoring of any ocular complaints that might arise during therapy. If any ophthalmic complications should occur, tamoxifen should be discontinued immediately. It is important to keep in mind that even low dose tamoxifen can induce ocular toxicity. The potential ocular toxicity of tamoxifen, even at low doses, can by no means be overlooked. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。